Economy

Seattle Genetics, Inc. (NASDAQ:SGEN) Hits 'Overbought' As Indicated by Its RSI(14)

(NASDAQ:SGEN) by 18.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. Vaughn Himes, an officer at (SGEN), bought 10000 shares at a price of 9.23 to bring his total ownership in the stock to 171,742 shares. Finally, Janus Capital Management LLC boosted its holdings in shares of Seattle Genetics by 321.2% in the first quarter. Hedge funds and other institutional investors own 97.63% of the company's stock. Andra AP fonden bought a new stake in Seattle Genetics during the 2nd quarter worth approximately $212,000. Dividends are mostly given in terms of cash payments, property or as shares of stock. It also reduced its holding in Facebook Inc (NASDAQ:FB) by 66,504 shares in the quarter, leaving it with 178,564 shares, and cut its stake in Spdr S&P 500 Etf (SPY). Janus Henderson Group PLC now owns 704,673 shares of the biotechnology company's stock valued at $36,460,000 after buying an additional 696,640 shares during the period. Spark Investment Management LLC grew its position in Seattle Genetics by 166.5% in the 2nd quarter. Janus Capital Management LLC now owns 527,400 shares of the biotechnology company's stock valued at $33,153,000 after buying an additional 402,200 shares during the period. Capital International Investors now owns 2,724,589 shares of the biotechnology company's stock valued at $140,970,000 after buying an additional 695,986 shares during the period. First Manhattan Co. raised its stake in Seattle Genetics by 31.3% during the 2nd quarter. M&T Bank Corp now owns 4,376 shares of the biotechnology company's stock worth $276,000 after buying an additional 297 shares during the last quarter. (SGEN). The consensus rating is 2.5, suggesting the market has given up on the stock. Seattle Genetics, Inc. (SGEN) has risen 75.68% since October 16, 2016 and is uptrending. The stock's average target of $16 is -16.45% below today's ($19.15) share price.

Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Seattle Genetics, Inc. Cann reiterated a "hold" rating on shares of Seattle Genetics in a research report on Friday, September 8th. SunTrust Banks, Inc. reissued a "hold" rating and issued a $45.00 target price on shares of Seattle Genetics in a report on Wednesday, October 4th. Royal Bank Of Canada started coverage on shares of Seattle Genetics in a research report on Thursday, September 14th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of "Hold" and an average price target of $61.00. Gotham Asset Management Ltd Llc has invested 0.02% in Seattle Genetics, Inc. (NASDAQ SGEN) traded down 0.73% on Monday, hitting $62.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Clay B. Siegall sold 25,506 shares of the business's stock in a transaction that occurred on Monday, August 28th. Shares for $156,182 were sold by Halligan Catherine Ann on Thursday, June 1. The disclosure for this sale can be found here. Insiders have sold 183,761 shares of company stock valued at $9,494,450 in the last ninety days. Current price level places the company's stock about -14.59% from the 52-week high and 271.24% away from the 52-week low. Seattle Genetics, Inc. has a 12 month low of $35.93 and a 12 month high of $75.36. (NASDAQ SGEN) opened at 65.95 on Monday.

Seattle Genetics, Inc. has a 50 day moving average of 54.50 and a 200 day moving average of 57.64. The company has market cap of $8.98 billion. (NASDAQ:SGEN) news were published by: Nasdaq.com which released: "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status" on October 03, 2017, also Nasdaq.com with their article: "Seattle Genetics' ADCETRIS Gets FDA Breakthrough Therapy Designation" published on October 02, 2017, Zacks.com published: "Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher October 03, 2017" on October 03, 2017. The biotechnology company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.03. After $-0.39 actual EPS reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth. The business had revenue of $108.20 million during the quarter, compared to analysts' expectations of $105.92 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. Seattle Genetics's quarterly revenue was up 13.4% compared to the same quarter previous year. On average, equities research analysts anticipate that Seattle Genetics, Inc. will post ($1.69) earnings per share for the current fiscal year.



Like this

Latest


17 October 2017
Should You Hold Rite Aid Corporation (NYSE:RAD)
Rite Aid Corporation (RAD ) stock price dropped with downswing change of -19.83% when it was compared to 20-day moving average. Rite Aid Corp ( RAD ) shares are showing negative signals short-term as the stock has finished lower by -11.22% for the week.

17 October 2017
Morgan Stanley Boosts Lincoln National Corporation (NYSE:LNC) Price Target to $77.00
On average, analysts forecast that Lincoln National Corporation will post $7.49 earnings per share for the current fiscal year. Following the sale, the director now directly owns 6,336 shares of the company's stock, valued at approximately $432,875.52.

17 October 2017
Remains found in crocodile believed to be missing Queensland pensioner
Environment Minister Steven Miles said the crocodile was euthanised. "It was very emotional for all those members involved". The woman reportedly became disorientated on a walk and headed into thick vegetation.

17 October 2017
How Does Pfizer Inc. (PFE) Stack Up Right Now?
The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Fisher Asset Management LLC increased its position in shares of Pfizer by 3.9% during the second quarter.

17 October 2017
New 3rd Party Console that Plays SNES Games Coming Next Year
The pint-sized remakes are loads of fun and make for great conversation pieces but they're not without faults and shortcomings. The Analogue team says it spent "thousands of hours" engineering the FPGA to be "free of compromises" for 16-bit gameplay.

17 October 2017
Institutional Investors Are Buying Sinclair Broadcast Group Inc (NASDAQ:SBGI)
It is positive, as 38 investors sold SBGI shares while 50 reduced holdings. 57 funds opened positions while 82 raised stakes. Any way you dice it, a dip below $28.02 a share would be very bad news for SBGI's technical picture in the near-term.

17 October 2017
Facebook acquires anonymous polling app targeted at teens
While the majority of online destinations are known for various degrees of toxic behavior, the app tbh aims to be different. Over 5 million people have downloaded the app and sent over a billion messages in the past few weeks, tbh said on Monday.

17 October 2017
Nuggets to sign Richard Jefferson, waive Jameer Nelson
Jefferson and Bucks' coach Jason Kidd spent five seasons together with the Nets from 2001-07. Several other teams have expressed interest in Jefferson , league sources told ESPN .

17 October 2017
Woman loses home in Santa Rosa wildfires after surviving Vegas massacre
Despite the two tragedies , Flores tells the news station that she's holding it together. She has been staying there while she moved to another apartment in the west of the city.

17 October 2017
Google beefs up Chrome's defences against unwanted add-ons
Additionally, it is easier to use thanks to a redesigned interface that better surfaces what software will be removed. If Chrome detects modifications, it will alert you with a dialog box that will allow you to roll back the changes.



Recommended